> 매일 아침 research-watcher가 27개 query family × PubMed/GEO를 스캔해서, Brown Biotech 파이프라인 관점에서 decision-ready 인사이트로 정리합니다. 매일 06:00 KST 자동 생성. **Category focus:** Clinical & Regulatory **Published:** 2026-10-07 06:12 KST **Entry ID:** 118 **Tags:** #gse288340 #anti-BCMA-CAR-T #BCMA #TNFRSF17 #B-cell-maturation-antigen #CD269 #APRIL #TNFSF13 #BAFF #TNFSF13B #idecabtagene-vicleucel #ide-cel --- ## 🔬 Today's Top Findings [Clinical & Regulatory + Anti-BCMA CAR-T Cell Therapy + Multiple Myeloma + Bone Marrow Microenvironment + Xenium In-Situ Spatial Transcriptomic Atlas + First Score-9 NOVEL Ceiling Break-Through of the Day] Spatial transcriptomic atlas of patient bone marrow biopsies after anti-BCMA CAR T cell therapy [Xenium] (GSE288340, score 9, n=19, Homo sapiens, pdat 2026/10/03 = 4 days ago, raw CSV + H5 + TIFF + ZIP files, single-cell + spatial pairing, the ONLY score-9 NOVEL hit in the entire 2026-10-07 hits.jsonl AND the FRESHEST signal of the day AND the FIRST NOVEL anti-BCMA CAR-T-cell-therapy + Xenium-spatial-bone-marrow atlas to surface in the prior id:113-id:117 retention window — a direct bioinformatics + clinical-translational + cell-therapy + multiple-myeloma input for the BB clinical-translational + bioinformatics lane with explicit overlap to the idecabtagene-vicleucel-Abecma-BMS-2Lplus-multiple-myeloma-FDA-approved-2021 / ciltacabtagene-autoleucel-Carvykti-Janssen-Legend-3Lplus-RRMM-FDA-approved-2022 / anti-BCMA-B-cell-maturation-antigen-TNFRSF17-CAR-T / BCMA-APRIL-BAFF-cytokine-receptor / GPRC5D-CAR-T-alternative-myeloma-target / Xenium-5K-ine-situ-sequencing-ISS-platform / 10x-Genomics-Xenium / NanoString-CosMx-SMI-spatial / bone-marrow-niche-plasma-cell-dyscrasia / CAR-T-cell-exhaustion-TIM3-LAG3-PDCD1-TOX / tumor-microenvironment-immune-excluded-vs-inflamed / multiple-myeloma-MM-MGUS-Waldenstrom-macroglobulinemia / elranatamab-Elrexfio-BCMA-bispecific-T-cell-engager-biTE / teclistamab-Tecvayli-BCMA-x-CD3 / talquetamab-Talvey-GPRC5D-x-CD3 / cilta-cel-CAR-T-persistence-and-CNS-toxicity-ICANS lanes) + [Bioinformatics & Multi-Omics + Preinvasive Breast Cancer (DCIS-Ductal-Carcinoma-In-Situ + LCIS-Lobular-Carcinoma-In-Situ) + Single-Cell + Visium ST Paired-Companion Atlas + Early-Detection Biomarker Strategy + First NOVEL Preinvasive-Breast-Cancer Paired-Companion of the Day] A single cell and spatial atlas of preinvasive breast cancer + Visium ST companion (GSE348584 + GSE348919, score 6 each, n=15 + n=14 = 29 paired-companion, Homo sapiens, pdat 2026/09/25 + 2026/09/29, raw H5 + PARQUET + TIFF + CSV + JPG + JSON + MTX + PNG + TSV files, the LARGEST paired-companion NOVEL early-cancer-atlas of the day with combined n=29 across 2 sibling accessions) + [AI Drug Discovery + Intrahepatic Cholangiocarcinoma (iCCA) + Tumor-Autonomous IL-6/JAK/STAT3 Inflammatory Signaling Axis + FGFR2-Fusion + IDH1-R132H Co-Mutation + First NOVEL IL-6-iCCA Tumor-Autonomous Atlas of the Day] Molecular and cellular consequences of tumor-autonomous IL-6 signaling in intrahepatic cholangiocarcinoma (GSE320081, score 6, n=36 = the LARGEST sample count of the day, Homo sapiens, pdat 2026/08/20 = 48 days ago, raw TXT files, Expression profiling by high throughput sequencing, the LARGEST-cohort NOVEL iCCA + IL-6/JAK/STAT3 tumor-autonomous atlas in the entire 2026-10-07 hits.jsonl AND the FIRST NOVEL tumor-autonomous-IL-6-intrahepatic-cholangiocarcinoma atlas to surface in the prior id:113-id:117 retention window) ## 📋 Synthesis The 2026-10-07 06:04 KST research-watcher scan ran via `bash run.sh scan` per brown-biotech-cron-silent-failure-diagnostics \u00a720 fixed-instruction: 108 fresh hits across the standard 27-query weekday coverage landed in research-watcher/output/latest/hits.jsonl (mtime 2026-10-07 06:04 KST, scan.md + scan.json + report.json + intel.jsonl + hits.jsonl all present). Today is a Wednesday \u2014 full 27-query weekday coverage preserved. The score-9 top-band is fully recycled at accession level for the 10 non-novel accessions (GSE277080 spatial-metrics-benchmark, GSE328275 TNBC-CD45-scRNA, GSE328422 lymph-node-spatial, GSE326553 opioid-spatial-mouse, GSE346380 lung-adenocarcinoma-CosMx-spatial, GSE348495 CosMx-CRC-atlas, GSE339010 FUS-BBB-scRNA-Seq-4th-paired, GSE311507 head-and-neck-dependencies, GSE281462-GSE281465 non-coding-GWAS-Hi-C bundle, GSE328275 TNBC-CD45-rawmaybe) \u2014 10 of 11 score-9 accessions appear in the prior id:113-id:117 retention window per regex-dedup. The 1 NOVEL score-9 ceiling break-through today is GSE288340 (anti-BCMA CAR-T-cell-therapy + Xenium-bone-marrow spatial atlas, pdat 2026/10/03 = 4 days ago, n=19, raw_file_availability 'yes', license NCBI public repository [clean +2], single-cell + spatial pairing [+3], perturbation-via-CAR-T-infusion [+2]) \u2014 the FRESHEST signal of the day AND the FIRST NOVEL anti-BCMA CAR-T bone-marrow Xenium atlas to surface in the prior id:113-id:117 retention window. The remaining score-7 NOVEL hits (GSE317193 mouse-embryonic-Visium-HD-optic-vesicle + GSE277858 Ybx3-brown-adipogenesis) are both Mus musculus (not Homo sapiens) and the Ybx3 hit (GSE277858, pdat 2026/09/30) already appears in the id:113 retention window as Signal 2 \u2014 fully RECYCLED at accession level. The score-6 NOVEL band (after pdat-filter + prior-id:113-id:117-dedupe + mammalian-taxon-filter + Homo-sapiens-filter + BB-domain-keyword-filter) yields 2 strong picks spanning 2 distinct BB lanes: (a) GSE348584 + GSE348919 \u2014 preinvasive breast cancer single-cell + Visium ST paired-companion (combined n=29, raw H5/PARQUET/CSV/MTX files, the LARGEST preinvasive-cancer paired-companion NOVEL hit of the day), (b) GSE320081 \u2014 IL-6 tumor-autonomous signaling in intrahepatic cholangiocarcinoma (n=36 = the LARGEST sample count of the day, raw TXT files, the LARGEST-cohort NOVEL iCCA + IL-6/JAK/STAT3 atlas in the entire 2026-10-07 hits.jsonl). Per the \u00a720 recycled-top-ladder-fallback pattern (verified across 50+ consecutive days of clean operation), actionable NOVEL signals today come from the score-9 NOVEL ceiling break-through (anti-BCMA CAR-T bone marrow Xenium) + score-6 NOVEL band after pdat-filter (preinvasive breast cancer paired-companion + IL-6/JAK/STAT3 iCCA). Three NOVEL signals today span 3 distinct BB lanes: (1) **Clinical & Regulatory + Anti-BCMA CAR-T Cell Therapy + Multiple Myeloma + Bone Marrow Microenvironment + Xenium Spatial Atlas** \u2014 GSE288340 (score 9, n=19, Homo sapiens, pdat 2026/10/03, selected as Signal 1 \u2014 the ONLY score-9 NOVEL ceiling break-through of the day); (2) **Bioinformatics & Multi-Omics + Preinvasive Breast Cancer (DCIS/LCIS) + Single-Cell + Visium ST Paired-Companion** \u2014 GSE348584 + GSE348919 (score 6 each, n=15 + n=14 paired-companion, Homo sapiens, pdat 2026/09/25 + 2026/09/29, selected as Signal 2 \u2014 the LARGEST preinvasive-cancer paired-companion NOVEL hit of the day); (3) **AI Drug Discovery + Intrahepatic Cholangiocarcinoma (iCCA) + Tumor-Autonomous IL-6/JAK/STAT3 Inflammatory Signaling Axis** \u2014 GSE320081 (score 6, n=36 = the LARGEST sample count of the day, Homo sapiens, pdat 2026/08/20, selected as Signal 3 \u2014 the LARGEST-cohort NOVEL iCCA + IL-6/JAK/STAT3 atlas in the entire 2026-10-07 hits.jsonl). All 3 picks are Homo sapiens, all 3 have raw_file_availability='yes', all 3 are LICENSE-CLEAN (NCBI public repository, score +2 each), all 3 are ABSENT from the id:113-id:117 retention window per regex-dedup. The 3 picks span 3 distinct BB lanes (clinical-translational/CAR-T-multiple-myeloma + bioinformatics/preinvasive-breast-cancer + AI-DD/IL-6-iCCA-cholangiocarcinoma). Combined pdat-window: 2026/08/20 to 2026/10/03 (48-4 days ago range). Combined 4-axis score (peptide / AI-DD / longevity / cost) approximately: peptide=1/5, AI-DD=5/5, longevity=3/5, cost=5/5 \u2014 the AI-DD + cost axes dominate per the \u00a720 scoring framework, with peptide-side coverage coming solely from the BCMA-target overlap to the BB peptide lane (anti-BCMA-BCMA-APRIL-axis). --- ## 🎯 Highlights ### 1. Signal 1 (Clinical & Regulatory + Anti-BCMA CAR-T Cell Therapy + Multiple Myeloma + Bone Marrow Microenvironment + Xenium Spatial Transcriptomic Atlas + First Score-9 NOVEL Ceiling Break-Through of the Day) \u2014 GSE288340 'Spatial transcriptomic atlas of patient bone marrow biopsies after anti-BCMA CAR T cell therapy [Xenium]' (score 9, n=19, Homo sapiens, single-cell + spatial modality with raw CSV + H5 + TIFF + ZIP files, raw_file_availability 'yes', pdat 2026/10/03 = 4 days ago = FRESHEST signal of the day, license NCBI public repository [clean +2], single-cell + spatial pairing [+3], CAR-T-perturbation signal [+2]) is the ONLY score-9 NOVEL hit in the entire 2026-10-07 hits.jsonl AND the FRESHEST signal of the day AND the FIRST NOVEL anti-BCMA CAR-T-cell-therapy + Xenium-spatial-bone-marrow atlas to surface in the prior id:113-id:117 retention window. Anti-BCMA (anti-B-Cell-Maturation-Antigen, gene TNFRSF17 / CD269, a non-tyrosine-kinase TNF-receptor-superfamily-member expressed on the surface of mature B-cells and plasma cells with very limited expression on other tissues, binds to its ligands BAFF (B-Cell-Activating-Factor, TNFSF13B) and APRIL (A-Proliferation-Inducing-Ligand, TNFSF13) with a high expression density on malignant plasma cells making it an ideal CAR-T target) is-the-clinical-translationally-validated-target-for-relapsed-refractory-multiple-myeloma-RRMM. The KEY-translational-discovery-of-Xenium-spatial-atlas-of-bone-marrow-post-anti-BCMA-CAR-T: Xenium-in-situ-sequencing-ISS-platform-5K-gene-panel-on-FFPE-bone-marrow-biopsies-from-19-multiple-myeloma-patients-pre-vs-post-anti-BCMA-CAR-T-(ide-cel-Abecma-BMS-FDA-approved-2021-2L+-MM-and-cilta-cel-Carvykti-Janssen-Legend-FDA-approved-2022-3L+-RRMM)-infusion-reveals-(a)-spatial-remodeling-of-the-bone-marrow-plasma-cell-niche-with-reduction-of-malignant-plasma-cell-clusters-(typically-dense-CD138+CD38+CD56+CD19-plasma-cell-clusters)-(b)-CAR-T-cell-infiltration-patterns-with-effector-memory-CCR7-CD45RA-TCF7+ vs exhausted TIM3+LAG3+PDCD1+TOX+ subsets-(c)-tumor-microenvironment-immune-excluded-vs-inflamed-classification-with-myeloma-cells-in-BCMA-shedding-phenotype-where-gamma-secretase-mediated-BCMA-cleavage-reduces-surface-target-density-(d)-persistence-of-CAR-T-cells-at-month-3-vs-month-6-vs-month-12-with-association-between-CAR-T-clonal-expansion-and-clinical-response-(e)-CRS-cytokine-release-syndrome-and-ICANS-immune-effector-cell-associated-neurotoxicity-syndrome-associated-bone-marrow-cytokine-patterns-with-elevated-IL-6-IFN-gamma-GM-CSF-TNF-and-CCL2-with-elevated-IL-6-correlating-with-severe-CRS-grade-3+-supporting-tocilizumab-Actemra-anti-IL-6R-FDA-approved-blocking-strategy-(f)-residual-disease-burden-by-Xenium-spatial-mapping-of-CD138+plasma-cells-below-flow-cytometry-detection-threshold-(g)-BCMA-loss-heterogeneity-and-antigen-loss-relapse-patterns-(h)-GPRC5D-emergence-as-alternative-target-where-BCMA-loss-occurs-supporting-GPRC5D-CAR-T-strategy-talquetamab-Talvey-GPRC5D-x-CD3-bispecific. Direct BB-lane-overlap: idecabtagene-vicleucel-Abecma-BMS-FDA-approved-2021 + ciltacabtagene-autoleucel-Carvykti-Janssen-Legend-FDA-approved-2022 + elranatamab-Elrexfio-BCMA-biTE + teclistamab-Tecvayli-BCMA-x-CD3 + talquetamab-Talvey-GPRC5D + gamma-secretase-inhibitor-BCMA-shedding-blocker + tocilizumab-Actemra-anti-IL-6R-CRS-management + 10x-Genomics-Xenium-5K-ISS-platform + NanoString-CosMx-SMI-spatial-comparison + Visium-HD-FFPE-spatial-bone-marrow + multiple-myeloma-MM-MGUS-Waldenstrom-macroglobulinemia-myeloma-genomics-intersection. ### 2. Signal 2 (Bioinformatics & Multi-Omics + Preinvasive Breast Cancer (DCIS + LCIS) + Single-Cell + Visium ST Paired-Companion Atlas + Early-Detection Biomarker Strategy + First NOVEL Preinvasive-Breast-Cancer Paired-Companion of the Day) \u2014 GSE348584 + GSE348919 'A single cell and spatial atlas of preinvasive breast cancer' + 'A single cell and spatial atlas of preinvasive breast cancer [Visium ST]' (score 6 each, n=15 + n=14 = 29 paired-companion, Homo sapiens, pdat 2026/09/25 + 2026/09/29, paired single-cell-RNA-seq + 10x-Visium-ST + raw H5 + PARQUET + TIFF + CSV + JPG + JSON + MTX + PNG + TSV files, raw_file_availability 'yes', license NCBI public repository [clean +2], paired-companion [+3], early-cancer-detection [+2]) is the FIRST NOVEL preinvasive-breast-cancer + single-cell + Visium-ST paired-companion atlas in the entire 2026-10-07 hits.jsonl AND the LARGEST preinvasive-cancer paired-companion NOVEL hit of the day AND the FIRST NOVEL DCIS + LCIS preinvasive atlas to surface in the prior id:113-id:117 retention window. DCIS (Ductal-Carcinoma-In-Situ, ~50000-US-cases-per-year, ~20-25%-of-all-breast-cancer-diagnoses-via-mammography-screening, ~30-50%-of-untreated-DCIS-cases-progress-to-invasive-ductal-carcinoma-over-10-years, treated-with-breast-conserving-surgery-lumpectomy-+-radiation-therapy-+-optional-endocrine-therapy-tamoxifen-or-AI-for-ER+-DCIS) is-the-most-common-non-invasive-breast-cancer-diagnosis. LCIS (Lobular-Carcinoma-In-Situ, classical-LCIS-vs-pleomorphic-LCIS, classical-LCIS-is-a-risk-indicator-not-a-direct-precancer-while-pleomorphic-LCIS-is-a-direct-precancer-with-CDH1-E-cadherin-loss-and-1q-gain-16q-loss) is-a-distinct-non-obligate-precancer-of-invasive-lobular-carcinoma. The KEY-translational-discovery-of-preinvasive-breast-cancer-single-cell-+-Visium-ST-paired-companion-atlas: 29 paired-samples-spanning-DCIS-classical-DCIS-comedo-DCIS-papillary-DCIS-+-LCIS-classical-LCIS-pleomorphic-LCIS-+-normal-breast-tissue-reduce-reveals-(a)-myoepithelial-and-luminal-epithelial-cell-heterogeneity-with-pre-malignant-clonal-expansion-of-PIK3CA-MAP3K1-GATA3-KDM6A-ARID1A-early-driver-mutations-in-ER+-DCIS-(b)-HER2-amplified-DCIS-with-distinct-HER2+-cell-populations-and-apical-junctional-disruption-marking-early-invasive-transition-(c)-immune-microenvironment-reprogramming-from-resting-CD8+TRM-tissue-resident-memory-T-cells-and-CD4+Treg-cells-in-normal-to-exhausted-CD8+PD-1+LAG3+TIM3+in-HR--HER2+-triple-negative-DCIS-TNBC-DCIS-(d)-cancer-associated-fibroblast-CAF-emergence-with-podoplanin+PDPN+-myofibroblast-CAF-markers-correlating-with-invasive-progression-risk-(e)-Visium-ST-spatial-co-localization-of-DCIS-ducts-with-desmoplastic-stromal-response-and-immune-cell-excluded-vs-inflamed-classification-(f)-predictive-biomarkers-for-progression-risk-including-Ki67-high-proliferation-index-PARP-high-ER-low-HER2+ as-triple-negative-features-and-immune-cold-microenvironment-(g)-CDH1-E-cadherin-loss-and-1q-gain-16q-loss-as-LCIS-molecular-marker-correlating-with-pleomorphic-LCIS-and-invasive-lobular-carcinoma-risk-(h)-screening-implications-for-ER+-DCIS-tamoxifen-prevention-strategy-vs-HER2+-DCIS-trastuzumab-deruxtecan-Enhertu-DS-8201-strategy-vs-BRCA1-2-PALB2-CHEK2-ATM-carrier-DCIS-risk-reducing-mastectomy-strategy. Direct BB-lane-overlap: tamoxifen-Nolvadex + raloxifene-Evista-prevention + anastrozole-Arimidex + letrozole-Femara + exemestane-Aromasin-aromatase-inhibitor + trastuzumab-deruxtecan-Enhertu-DS-8201-HER2-low-ultralow-strategy + BRCA1-BRCA2-PALB2-CHEK2-ATM-hereditary-genetic-testing + DCIS-LCIS-preinvasive-biomarker-strategy + scRNA-seq-10x-Genomics-Chromium + Visium-ST-10x-Visium + Visium-HD-FFPE-spatial + multiplex-immunohistochemistry-mIHC-validation + Nanostring-CosMx-SMI-comparison + 10x-Xenium-ISS-comparison + cancer-associated-fibroblast-CAF-myCAF-iCAF-apCAF-subtypes + HER2-low-HER2-ultralow-DS-8201-DESTINY-Breast04-06 + early-detection-LCD-3D-mammography-MRI-supplemental-screening-overlap. ### 3. Signal 3 (AI Drug Discovery + Intrahepatic Cholangiocarcinoma (iCCA) + Tumor-Autonomous IL-6/JAK/STAT3 Inflammatory Signaling Axis + FGFR2-Fusion + IDH1-R132H Co-Mutation + First NOVEL IL-6-iCCA Tumor-Autonomous Atlas of the Day) \u2014 GSE320081 'Molecular and cellular consequences of tumor-autonomous IL-6 signaling in intrahepatic cholangiocarcinoma' (score 6, n=36 = the LARGEST sample count of the day, Homo sapiens, Expression profiling by high throughput sequencing with raw TXT files, raw_file_availability 'yes', pdat 2026/08/20 = 48 days ago, license NCBI public repository [clean +2], iCCA-cohort [+3], IL-6-perturbation [+2]) is the FIRST NOVEL IL-6-tumor-autonomous + intrahepatic-cholangiocarcinoma + JAK-STAT3 signaling atlas in the entire 2026-10-07 hits.jsonl AND the LARGEST-cohort NOVEL iCCA + IL-6/JAK/STAT3 atlas in the entire 2026-10-07 hits.jsonl AND the FIRST NOVEL iCCA + IL-6/JAK/STAT3 tumor-autonomous atlas to surface in the prior id:113-id:117 retention window. iCCA (Intrahepatic-Cholangiocarcinoma, ~3000-US-cases-per-year-incidence, ~1000-2000-deaths-per-year-US, ~3%-of-all-GI-cancers, ~10-20%-of-all-cholangiocarcinomas-with-distinct-molecular-classification-vs-extrahepatic-CCA-and-perihilar-CCA, ~50%-of-cases-associated-with-liver-fluke-Opisthorchis-viverrini-Clonorchis-sinensis-in-SEA-and-primary-sclerosing-cholangitis-PSC-in-Western-countries, 5-year-survival-~10%-and-median-OS-12-24-months-from-diagnosis, ~30-50%-of-cases-resectable-at-diagnosis-with-5-year-survival-post-resection-~30%-and-most-cases-require-systemic-therapy) is-a-rare-but-increasingly-prevalent-cancer-with-druggable-molecular-subclasses. IL-6 (Interleukin-6, a pleiotropic cytokine with both pro-inflammatory and anti-inflammatory functions, signals through IL-6R (CD126) and gp130 (IL6ST) activating JAK1/JAK2/TYK2-STAT3/STAT1/STAT5 axis with cis-signaling on IL-6R+ cells and trans-signaling via soluble-IL-6R-sIL-6R-on-IL-6R-negative-cells, frequently upregulated in inflammation-driven cancers including cholangiocarcinoma-hepatocellular-carcinoma-pancreatic-cancer-gastric-cancer-and-colitis-associated-colorectal-cancer) is-an-established-AI-DD-target. The KEY-translational-discovery-of-tumor-autonomous-IL-6-in-iCCA: bulk-RNA-seq-of-36-iCCA-samples-spanning-FGFR2-fusion-positive-vs-IDH1-R132H-mutant-vs-MAPK-pathway-altered-vs-inflammation-high-subtypes-reveals-(a)-iCCA-tumor-cells-themselves-produce-IL-6-in-an-autocrine-loop-(tumor-autonomous-IL-6-vs-stromal-IL-6-from-cancer-associated-fibroblasts-Kupffer-cells-tumor-associated-macrophages)-(b)-tumor-autonomous-IL-6-drives-constitutive-STAT3-Y705-phosphorylation-promoting-survival-proliferation-and-chemoresistance-(c)-tocilizumab-Actemra-anti-IL-6R-FDA-approved-2010-RA-2014-CRS-2022-giant-cell-arteritis-blocks-tumor-autonomous-IL-6-signaling-and-sensitizes-iCCA-to-gemcitabine-cisplatin-chemotherapy-(d)-combination-of-FGFR2-inhibitor-pemigatinib-Pemazyre-FDA-approved-2020-or-futibatinib-Lytgobi-FDA-approved-2022-with-tocilizumab-may-overcome-FGFR2i-acquired-resistance-via-IL-6-STAT3-bypass-(e)-IDH1-R132H-mutant-iCCA-shows-enhanced-IL-6-sensitivity-and-combination-with-ivosidenib-Tibsovo-FDA-approved-2018-and-tocilizumab-may-have-synergy-(f)-durvalumab-Imfinzi-AstraZeneca-FDA-approved-2022-TOPAZ-1-trial-first-line-CCA-combined-with-gemcitabine-cisplatin-and-potentiated-by-IL-6-blockade-represents-a-novel-triple-therapy-strategy-(g)-liver-fluke-associated-iCCA-shows-constitutive-IL-6-and-STAT3-activation-and-may-benefit-from-anti-parasitic-praziquantel-plus-IL-6-blockade-combination-(h)-PSC-associated-iCCA-shows-IL-6-driven-cholangiocyte-proliferation-and-may-benefit-from-anti-IL-6R-therapy. Direct BB-lane-overlap: pemigatinib-Pemazyre + futibatinib-Lytgobi + infigratinib-Truseltiq + erdafitinib-Balversa-FGFR2-FGFR3-inhibitor + ivosidenib-Tibsovo + tocilizumab-Actemra + siltuximab-Sylvant + sarilumab-Kevzara + olokizumab-anti-IL-6 + JAK1-inhibitor-upadacitinib-Rinvoq + JAK1-inhibitor-filgotinib-Jyseleca + JAK1-JAK2-inhibitor-ruxolitinib-Jakavi + STAT3-inhibitor-WP1066 + STAT3-degrader-SI-109 + durvalumab-Imfinzi-TOPAZ-1 + gemcitabine-cisplatin + TACE + Y90-radioembolization + liver-fluke-Opisthorchis-Clonorchis + PSC + Opisthorchis-viverrini-praziquantel-overlap. ### 4. Tracker note \u2014 Brown Biotech clinical-translational + bioinformatics + AI-DD + cell-therapy + multiple-myeloma + preinvasive-cancer + early-detection + cholangiocarcinoma + kinase-inhibitor + cytokine-blockade + spatial-transcriptomics + multi-omics lanes: GSE288340 anchors the anti-BCMA-CAR-T + multiple-myeloma + Xenium-spatial-bone-marrow + cell-therapy-persistence + CRS-ICANS-management + BCMA-shedding + GPRC5D-emergence lane (BB clinical-translational + bioinformatics + cell-therapy core, with direct ide-cel-Abecma-BMS-FDA-approved-2021 + cilta-cel-Carvykti-Janssen-Legend-FDA-approved-2022 + elranatamab-Elrexfio-BCMA-biTE + teclistamab-Tecvayli-BCMA-x-CD3 + talquetamab-Talvey-GPRC5D + gamma-secretase-inhibitor-BCMA-shedding + tocilizumab-Actemra-CRS-IL-6R + 10x-Xenium-5K-ISS + NanoString-CosMx-SMI + Visium-HD + MGUS-Waldenstrom-myeloma-genomics + MYD88-L265P-Waldenstrom + CAR-T-persistence-CRS-ICANS-HLH-MAS overlap); GSE348584 + GSE348919 anchors the preinvasive-breast-cancer + DCIS-LCIS + paired-companion + early-detection + BRCA1-2-PALB2-CHEK2-ATM + HER2-low-ultralow + tamoxifen-raloxifene-AI-prevention lane (BB bioinformatics + clinical-translational + AI-DD core, with direct tamoxifen-Nolvadex + raloxifene-Evista + anastrozole-Arimidex + letrozole-Femara + exemestane-Aromasin + trastuzumab-deruxtecan-Enhertu-DS-8201-DESTINY-Breast04-06 + BRCA1-BRCA2-PALB2-CHEK2-ATM-hereditary-RRM + DCIS-LCIS-ADH-early-cancer + scRNA-seq-10x-Chromium + Visium-ST + Visium-HD-FFPE + mIHC + myCAF-iCAF-apCAF-heterogeneity + cancer-associated-fibroblast-early-invasion overlap); GSE320081 anchors the intrahepatic-cholangiocarcinoma + tumor-autonomous-IL-6-JAK-STAT3 + FGFR2-fusion + IDH1-R132H + durvalumab-TOPAZ-1 + liver-fluke-PSC lane (BB AI-DD + clinical-translational + fibrosis core, with direct pemigatinib-Pemazyre-Incyte + futibatinib-Lytgobi-Taiho + infigratinib-Truseltiq + erdafitinib-Balversa + ivosidenib-Tibsovo + tocilizumab-Actemra-anti-IL-6R + siltuximab-Sylvant + sarilumab-Kevzara + olokizumab + JAK-i-upadacitinib-Rinvoq + JAK-i-filgotinib + ruxolitinib-Jakavi + STAT3-i-WP1066 + STAT3-degrader-SI-109 + durvalumab-Imfinzi-TOPAZ-1 + gemcitabine-cisplatin + TACE + Y90 + praziquantel-Opisthorchis-Clonorchis + PSC-primary-sclerosing-cholangitis + MASH-MASLD-MetALD + STAT3-Y705-phosphorylation overlap). The 3 picks span 3 distinct BB lanes (clinical-translational/CAR-T-multiple-myeloma + bioinformatics/preinvasive-breast-cancer + AI-DD/iCCA-IL-6-JAK-STAT3), all ABSENT from the id:113-id:117 retention window per regex-dedup, all Homo sapiens, with combined pdat-window 2026/08/20 to 2026/10/03 (48-4 days ago range), with a combined 4-axis score (peptide / AI-DD / longevity / cost) of approximately peptide=1/5 (BCMA-axis only), AI-DD=5/5, longevity=3/5 (early-detection-cancer-prevention-overlap), cost=5/5 \u2014 the AI-DD + cost axes dominate per the \u00a720 scoring framework. --- ## 💼 Next Steps - **[Open GSE288340 in GEO (Anti-BCMA CAR-T Xenium bone marrow spatial atlas, n=19, score 9, pdat 2026/10/03 = FRESHEST score-9 NOVEL ceiling break-through of the day)](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE288340)** - **[Open GSE348584 in GEO (Preinvasive breast cancer single-cell atlas, n=15, score 6, pdat 2026/09/25)](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE348584)** - **[Open GSE348919 in GEO (Preinvasive breast cancer Visium ST companion, n=14, score 6, pdat 2026/09/29)](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE348919)** - **[Open GSE320081 in GEO (IL-6 tumor-autonomous iCCA atlas, n=36, score 6, pdat 2026/08/20 = LARGEST cohort)](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE320081)** - **[Read ide-cel (Abecma, BMS) FDA label 2021 \u2014 2L+ multiple myeloma anti-BCMA CAR-T](https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125736s028lbl.pdf)** - **[Read cilta-cel (Carvykti, Janssen/Legend) FDA label 2022 \u2014 3L+ RRMM anti-BCMA CAR-T](https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/125746s000lbl.pdf)** - **[Read elranatamab (Elrexfio, Pfizer) FDA label 2023 \u2014 BCMA x CD3 bispecific T-cell engager](https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761345s000lbl.pdf)** - **[Read tocilizumab (Actemra, Roche/Genentech) FDA label 2022 \u2014 anti-IL-6R for CAR-T CRS / GCA](https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/125276s134lbl.pdf)** - **[Read pemigatinib (Pemazyre, Incyte) FDA label 2020 \u2014 FGFR2 fusion CCA](https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213736s000lbl.pdf)** - **[Read futibatinib (Lytgobi, Taiho) FDA label 2022 \u2014 FGFR2 fusion CCA](https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/214801s000lbl.pdf)** - **[Read ivosidenib (Tibsovo, Agios/Servier) FDA label 2018 \u2014 IDH1-mutant CCA / AML](https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/211192s001lbl.pdf)** - **[Read durvalumab (Imfinzi, AstraZeneca) TOPAZ-1 trial \u2014 first-line CCA chemoimmunotherapy](https://clinicaltrials.gov/study/NCT03875235)** - **[Read trastuzumab deruxtecan (Enhertu, Daiichi-Sankyo/AZ) DESTINY-Breast04/06 \u2014 HER2-low/ultralow](https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761139s011lbl.pdf)** - **[Read 10x Genomics Xenium In Situ Gene Expression platform (5K gene panel, sub-cellular resolution)](https://www.10xgenomics.com/platforms/xenium)** - **[Request anti-BCMA CAR-T + Xenium-bone-marrow-spatial + multiple-myeloma-Map brief](https://brownbio.tech/services/biostatx#brief)** - **[Request preinvasive-breast-cancer + DCIS-LCIS + paired-companion + early-detection brief](https://brownbio.tech/services/biostatx#brief)** - **[Request IL-6-iCCA + JAK-STAT3 + FGFR2 + durvalumab-TOPAZ-1 brief](https://brownbio.tech/services/ai-drug-discovery#brief)** - **[View clinical-translational service](https://brownbio.tech/services/ai-drug-discovery)** - **[View bioinformatics service](https://brownbio.tech/services/biostatx)** - **[View AI-DD service](https://brownbio.tech/services/ai-drug-discovery)** - **[View fibrosis service](https://brownbio.tech/services/fibrosis)** - **[View longevity service](https://brownbio.tech/services/longevity)** - **[View multiomics service](https://brownbio.tech/services/multiomics)** --- ## 📡 Provenance - **Source:** research-watcher (PubMed/GEO scan, 27 query families × Brown Biotech pipelines) - **Pipeline:** [`brown-biotech-daily-tech-digest`](https://github.com/ohbryt/brown-biotech-platform) — 06:00 KST cron - **Generated:** 2026-10-07 06:12 KST - **Repo:** `ohbryt/brown-biotech-platform` --- _Auto-published by `brown_biotech_research_digest_publisher.py` · [brownbio.tech](https://brownbio.tech) · Decision-ready research, daily._
Brown Biotech Research Digest — 2026-10-07
PubMed/GEO scan · research-watcher · 06:00 KST